Wall Street slips as Merck drops, tax talk rattles

Go back to Wall Street slips as Merck drops, tax talk rattles

Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'

October 30, 2017 10:45 AM EDT

UBS lowered its price target on Merck (NYSE: MRK) to $67.00 (from $72.00) while maintaining a Buy rating, following the announcement that management would push out results into early 2019 for Keynote-189 in lung cancer.

Analyst Marc Goodman notes a cautious outlook on the shares as... More